Shanghai Haohai Biological Technology Crecimiento futuro
Future controles de criterios 3/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Shanghai Haohai Biological Technology de 18.2% y 15.2% respectivamente, mientras que el BPA disminuirá en un 0.5% al año.
Información clave
18.2%
Tasa de crecimiento de los beneficios
-0.5%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 35.1% |
Tasa de crecimiento de los ingresos | 15.2% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 06 Jun 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Can Mixed Fundamentals Have A Negative Impact on Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Current Share Price Momentum?
Feb 23What Type Of Shareholders Own The Most Number of Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Shares?
Feb 05Does Shanghai Haohai Biological Technology's (HKG:6826) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 21Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Should Think About This Before Buying It For Its Dividend
Jan 06We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Dec 22Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2025 | 3,522 | 599 | N/A | N/A | 1 |
12/31/2024 | 3,097 | 519 | N/A | N/A | 1 |
3/31/2024 | 2,689 | 432 | 239 | 630 | N/A |
12/31/2023 | 2,654 | 416 | 367 | 634 | N/A |
9/30/2023 | 2,503 | 346 | 99 | 442 | N/A |
6/30/2023 | 2,453 | 315 | 92 | 401 | N/A |
3/31/2023 | 2,278 | 248 | 3 | 316 | N/A |
12/31/2022 | 2,130 | 180 | -86 | 231 | N/A |
9/30/2022 | 2,063 | 203 | 52 | 343 | N/A |
6/30/2022 | 1,861 | 192 | 57 | 336 | N/A |
3/31/2022 | 1,805 | 272 | 64 | 339 | N/A |
12/31/2021 | 1,750 | 352 | 70 | 342 | N/A |
9/30/2021 | 1,702 | 428 | 115 | 333 | N/A |
6/30/2021 | 1,674 | 434 | 120 | 342 | N/A |
3/31/2021 | 1,594 | 370 | N/A | N/A | N/A |
12/31/2020 | 1,324 | 230 | 66 | 262 | N/A |
9/30/2020 | 1,343 | 232 | -20 | 258 | N/A |
6/30/2020 | 1,306 | 216 | 6 | 258 | N/A |
3/31/2020 | 1,437 | 279 | N/A | N/A | N/A |
12/31/2019 | 1,595 | 371 | -50 | 349 | N/A |
9/30/2019 | 1,537 | 353 | -8 | 286 | N/A |
6/30/2019 | 1,570 | 386 | -7 | 302 | N/A |
3/31/2019 | 1,478 | 375 | N/A | N/A | N/A |
12/31/2018 | 1,546 | 415 | 239 | 391 | N/A |
9/30/2018 | 1,523 | 411 | 235 | 398 | N/A |
6/30/2018 | 1,501 | 408 | 231 | 404 | N/A |
3/31/2018 | 1,423 | 390 | 220 | 374 | N/A |
12/31/2017 | 1,345 | 372 | N/A | 343 | N/A |
9/30/2017 | 1,214 | 351 | N/A | 330 | N/A |
6/30/2017 | 1,083 | 329 | N/A | 317 | N/A |
3/31/2017 | 967 | 317 | N/A | 286 | N/A |
12/31/2016 | 851 | 305 | N/A | 254 | N/A |
9/30/2016 | 787 | 295 | N/A | 245 | N/A |
6/30/2016 | 724 | 284 | N/A | 235 | N/A |
3/31/2016 | 694 | 279 | N/A | 252 | N/A |
12/31/2015 | 664 | 273 | N/A | 269 | N/A |
9/30/2015 | 630 | 258 | N/A | 244 | N/A |
6/30/2015 | 597 | 243 | N/A | 219 | N/A |
3/31/2015 | 556 | 213 | N/A | 181 | N/A |
12/31/2014 | 516 | 184 | N/A | 142 | N/A |
9/30/2014 | 482 | 169 | N/A | 135 | N/A |
6/30/2014 | 449 | 154 | N/A | 128 | N/A |
3/31/2014 | 425 | 148 | N/A | 137 | N/A |
12/31/2013 | 401 | 142 | N/A | 147 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (18.2% al año) de 6826 es superior a la tasa de ahorro (2.2%).
Beneficios vs. Mercado: Se prevé que los beneficios (18.2% al año) de 6826 crezcan más rápidamente que el mercado Hong Kong (11.8% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de 6826 crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (15.2% al año) de 6826 crezcan más rápidamente que los del mercado Hong Kong (7.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 15.2% al año) de 6826 crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 6826 se prevé que sea elevada dentro de 3 años.